Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Trintellix | Vortioxetine | Depression, major depressive disorder | Withdrawn | |||
| Victoza | Liraglutide | Diabetes Mellitus, Type 2 | Withdrawn | |||
| Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
| Avastin | Bevacizumab | Withdrawn | ||||
| Onglyza | Saxagliptin | Diabetes mellitus, type 2 | Withdrawn | |||
| Xarelto | Rivaroxaban | Deep-vein thrombosis without symptomatic pulmonary embolism | Complete | |||
| Myrbetriq | Mirabegron | Overactive bladder | Withdrawn | |||
| Invokana | Canagliflozin | Diabetes Mellitus, Type 2 | Withdrawn | |||
| Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, Type 2 | Withdrawn | |||
| Lemtrada | Alemtuzumab | Multiple sclerosis, relapsing-remitting | Withdrawn |
Last Updated : April 27, 2024